Pneumocystis jirovecii

From IDWiki
Pneumocystis jirovecii /
Revision as of 18:06, 11 August 2019 by Maintenance script (talk | contribs) (Imported from text file)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Pneumocystis jirovecii pneumonia (PJP)

Etiology

  • Lower respiratory infection caused by Pneumocystis jirovecii

Epidemiology

  • HIV
  • Immune-suppression, e.g. from steroids

Presentation

  • Shortness of breath on exertion

Investigations

  • CXR
  • Typical: bilateral diffuse patchy disease
  • Atypical:
    • Normal (15%)
    • Localized
    • Pneumothorax
    • Upper lobe, if on pentamidine
  • LDH increased
  • CBC often normal

Diagnosis

  • Induced sputum or brochoalveolar lavage (normal sputum not sensitive enough)
  • 6min walk test: will desaturate, even if well-oxygenated at rest

Treatment

  • Septra 5-6mg/kg po BID for 3 weeks
  • If pO2 <70mmHg or A-a gradient ≥35: prednisone
  • Alternative: clindamycin-primaquine or IV pentamidine
  • Duration is 21 days (3 weeks)

Prophylaxis

  • Usually instituted if the risk of PJP is greater than 3.5% per year

References

  1. ^  Po-Yi Chen, Chong-Jen Yu, Jung-Yien Chien, Po-Ren Hsueh. Anidulafungin as an alternative treatment for Pneumocystis jirovecii pneumonia in patients who could not tolerate Trimethoprim/sulfamethoxazole. International Journal of Antimicrobial Agents. 2019. doi:10.1016/j.ijantimicag.2019.10.001.
  2. ^  L. Cooley, C. Dendle, J. Wolf, B. W. Teh, S. C. Chen, C. Boutlis, K. A. Thursky. Consensus guidelines for diagnosis, prophylaxis and management ofPneumocystis jiroveciipneumonia in patients with haematological and solid malignancies, 2014. Internal Medicine Journal. 2014;44(12b):1350-1363. doi:10.1111/imj.12599.
  3. ^  N. Goto, S. Oka. Pneumocystis jirovecii pneumonia in kidney transplantation. Transplant Infectious Disease. 2011;13(6):551-558. doi:10.1111/j.1399-3062.2011.00691.x.